New cancer treatment yields promising results

A group of researchers conducted a study on one of the modern treatments for the treatment of lymphoma patients, and in promising results, researchers found the effectiveness of a treatment that was recently used to help people with malignant disease in the United States.

According to what “Deutsche Welle” reported, researchers at the University of Michigan’s Rogel Cancer Center found that, depending on the new treatment, the size of the tumor was reduced in 80 percent of patients, while the tumor was still completely complete in a percentage ranging between 18 and 20 percent.

And participated in the clinical trial conducted by the university, 20 patients with slow-growing marginal lymphoma and 33 others with follicular lymphoma, and the University of Michigan Medical School website said that the side effects of the oral treatment ranged from high temperatures, diarrhea and rashes. And low levels of white blood cells in the blood, which are part of the immune system and an essential component of resistance to disease and infection.

And the treatment had obtained the necessary permission for its medical use in the United States at the end of 2019, according to the US Food and Drug Agency “FDA” website, and after the results of that study, along with other similar studies, the American authorities approved the use of the treatment conditionally to treat lymphoma. If the tumor recurs after treatment or if it does not respond to other types of treatment.

Zanubrutinib is an inhibitor of drugs that blocks the enzyme that controls the nerve-signaling pathway that lymphomas depend on to survive and grow in the patient's body.

Although the limited number of participants in clinical trials limits the ability to generalize the findings, the findings regarding safety and efficacy highlight the drug's potential as an additional Available treatments for this cancer.

Follow our latest local and sports news and the latest political and economic developments via Google news